Identification and Validation of Novel and More Effective Choline Kinase
Total Page:16
File Type:pdf, Size:1020Kb
www.nature.com/scientificreports OPEN Identifcation and validation of novel and more efective choline kinase inhibitors against Streptococcus pneumoniae Tahl Zimmerman1*, Valerie Chasten1, Juan Carlos Lacal2 & Salam A. Ibrahim1 Streptococcus pneumoniae choline kinase (sChoK) has previously been proposed as a drug target, yet the efectiveness of the frst and only known inhibitor of sChoK, HC-3, is in the millimolar range. The aim of this study was thus to further validate sChoK as a potential therapeutic target by discovering more powerful sChoK inhibitors. LDH/PK and colorimetric enzymatic assays revealed two promising sChoK inhibitor leads RSM-932A and MN58b that were discovered with IC50 of 0.5 and 150 μM, respectively, and were shown to be 2–4 magnitudes more potent than the previously discovered inhibitor HC-3. Culture assays showed that the minimum inhibitory concentration (MIC) of RSM- 932A and MN58b for S. pneumoniae was 0.4 μM and 10 μM, respectively, and the minimum lethal concentration (MLC) was 1.6 μM and 20 μM, respectively. Western blot monitoring of teichoic acid production revealed diferential patterns in response to each inhibitor. In addition, both inhibitors possessed a bacteriostatic mechanism of action, and neither interfered with the autolytic efects of vancomycin. Cells treated with MN58b but not RSM-932A were more sensitive to a phosphate induced autolysis with respect to the untreated cells. SEM studies revealed that MN58b distorted the cell wall, a result consistent with the apparent teichoic acid changes. Two novel and more highly potent putative inhibitors of sChoK, MN58b and RSM-932A, were characterized in this study. However, the efects of sChoK inhibitors can vary at the cellular level. sChoK inhibition is a promising avenue to follow in the development of therapeutics for treatment of S. pneumoniae. Te efectiveness of current therapeutics for pathogens such as S. pneumoniae has dropped with the emergence of resistant strains. Consequently, new methods for treating S. pneumoniae have to be developed continuously. Tis includes establishing novel targets for drug discovery eforts. Recently, choline kinase (ChoK) has been proposed as a drug target for Gram positive species generally 1 afer the frst ChoK inhibitor capable of inhibiting the growth of S. pneumoniae was discovered2,3. Like its eukaryotic counterparts, bacterial ChoKs phosphorylate choline (Cho) into phosphocholine (PCho). PCho is a precursor molecule that is utilized in the production of two types of teichoic acids: lipoteichoic acid (LTA) and cell wall teichoic acid (CTA)4,5. In S. pneumoniae, both LTA and CTA consist of the same types of polysaccharides; however, LTA is attached to a lipid and embedded in the cell membrane, and CTA is attached to the cell wall peptidoglycan layer in the cell wall 6. LTA is an important virulence factor 7, and production of this molecule has been validated as a drug target8. Choline is an essential nutrient for S. pneumoniae9, and the choline kinase of S. pneumoniae (sChoK) is an essential enzyme10. Te sChoK enzyme is an element of the pathway that mediates the decoration of teichoic acids with PCho via the intermediary CDP-choline. Genes that are part of this pathway are expressed via the lic gene locus. Te LicB gene expresses a Cho transporter which collects Cho from the external environment. LicA codes for sChoK, which phosphorylates Cho into PCho. LicC is a gene coding for cytidylyl transferase, which converts PCho into CDP-choline. Te LicD1 and LicD2 PCho transferases remove PCho from CDP-choline and attach them to N-acetylgalactosamine (GalNAc) residues located on pre-teichoic acid glycan subunits 11. Tese 1Food Microbiology and Biotechnology Laboratory, Department of Family and Consumer Sciences, College of Agriculture and Environmental Sciences, North Carolina A&T State University, 1601 East Market Street, Greensboro, NC 27411, USA. 2Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científcas, c/ Arturo Duperier 4, 28029 Fuenlabrada, Madrid, Spain. *email: [email protected] SCIENTIFIC REPORTS | (2020) 10:15418 | https://doi.org/10.1038/s41598-020-72165-6 1 Vol.:(0123456789) www.nature.com/scientificreports/ Figure 1. (A) MN58b (green) and RSM-932A (red) docked onto the crystal structure of apo-sChoK (accession #4R77) as well as the positions of the natural substrates choline (blue) and AMP (yellow); (B) a close up view of the binding sites; (C) Structures of RSM-932A (1,1′-([1,1′-biphenyl]-4,4′-diylbis(methylene))bis(4-((4- chlorophenyl)(methyl)amino)quinolin-1-ium) bromide) and MN58b (1,4-[4–4′-Bis-{[4-(dimethylamine) pyridinium-1-yl]methyl}diphenyl]butane dibromide). residues are then polymerized by an unidentifed protein to form teichoic acid which is11 transported across the cell membrane acid fippase TacF. Te TacL ligase attaches teichoic polymers to a glycolipid anchor to form LTA7. Meanwhile, teichoic acid polymers are cross-linked to peptidoglycan to form WTA by the action of LCP phosphotransferases11. Te enzyme of S. pneumoniae has previously been proposed as a drug target3. However, the sChoK inhibitor 12 originally tested, Hemicholinium-3 (HC-3), was weak: HC-3 had IC50 and minimum inhibitory concentra- tion (MIC) values in the millimolar range3. Te aim of this study was to discover stronger inhibitors of sChoK in order to further establish sChoK as a target. Here, we present two compounds which strongly inhibit sChoK activity and S. pneumoniae growth and viability: MN58b and RSM-932A (Fig. 1C)13,14, two compounds known to inhibit human choline kinase (hChoK)14. Using S. pneumoniae as a model, we present evidence to demonstrate that employing sChoK inhibitors is a promising strategy for blocking the growth of S. pneumoniae cells. Tese inhibitors, in turn, were found to have downstream efects on teichoic acid production and assembly, on cell wall shape, and on the sensitivity of the cell to autolysis. SCIENTIFIC REPORTS | (2020) 10:15418 | https://doi.org/10.1038/s41598-020-72165-6 2 Vol:.(1234567890) www.nature.com/scientificreports/ Methods and materials Recombinant sChoK expression and purifcation. A pET28a/sChoK construct was generously pro- vided to us by the group of Dr. Yuxing Chen15 and transformed into BL21 (DE3) cells. Cells were cultured at 200 rpm at 37 °C until an O.D.600 of 0.6 was reached and then induced with 1 mM IPTG overnight at 25 °C. Cells were then harvested by centrifugation and stored at − 20 °C. Cell lysis was performed by suspending each gram of pellet with 5 mL of B-PER Complete Bacterial Protein Extraction Reagent (Termo-Scientifc) per gram of cell. Te enzyme sChoK was purifed using HisPur Ni-NTA Resin (Termo Scientifc). Determining steading state kinetic constants by LDH/PK. Purifed sChoK was used in these assays. Steady-state enzymatic assays were monitored with the pyruvate kinase/lactate dehydrogenase (PK/LDH) reac- tion. Te steady-state rate of ADP formation was calculated using an extinction coefcient of 6,200 M−1 cm−1 to determine linear reductions in NADH concentrations that were observed by absorbance at 340 nm. Measure- ments were carried out at 25 °C in a UV-Star 96-well plate (Greiner) placed in a Synergy HT microplate reader (Biotek). Each well contained 200 µL of a solution containing 22 nM sChoK enzyme, 100 mM Tris pH 8, 10 mM MgCl2, 150 mM NaCl, 150 mM KCl, 100 mM NADH, 0.66 mM phosphoenolpyruvate, 20 units of LDH, and 10 units of PK, choline. ATP. Km and Vmax values were derived by plotting initial velocities against the substrate concentration and ftting this data into Eq. (1). v0 = (Vmax[S])/(Km +[S]) (1) where v0 is the initial velocity [S] = substrate concentration; Vmax = maximum velocity; and Km is the concentration at half-maximal velocity. Te kcat was calculated by dividing the Vmax by the enzyme concentration. Determining IC50 by LDH/PK. Using the conditions described above, the concentration of choline was set to the Km and increasing amounts of inhibitor were tested. Percent inhibition was determined. Te IC50 was determined as the concentration of inhibitor required to reach 50% inhibition. Determining IC50 colorimetrically. When using cell extracts such as BL21 (DE3) extracts containing sChoK or S. pneumoniae extracts as the enzyme source, a colorimetric method was used to quantify Cho con- sumption and PCho production as described previously16. Determining MN58b and RSM-932A competitivity by LDH/pK. Te mechanism of action of the inhibitors with respect to each substrate was determined using a previously described method13,14. Briefy, using the IC50 of each inhibitor determined at the Km of choline, the concentration of one substrate was kept constant, and initial velocities were measured while varying the second substrate in the presence and absence of the inhibi- tor. Te percentage of inhibition (%I) was determined by dividing each initial velocity in the presence of the inhibitor with its corresponding initial velocity in the absence of compound. %I was plotted against concentra- tion and ftted using a two-parameter-ft nonlinear regression algorithm of GnuPlot v 4.3 into Eq. (2). %I = 100 × (([I]/Ki +[S][I]/αKsKi/(1 +[S]/Ks +[I]/Ki +[S][I]/αKsKi)) (2) where [S] is the concentration of the varied substrate, [I] is the concentration of inhibitor, Ks is the dissociation constant of the substrate (assumed to be equal to the K m), Ki is the dissociation constant of the inhibitor, and α is a numerical constant that measures the efect the substrate has on the binding of the inhibitor and vice versa. Docking of MN58b and RSM-932A onto sChoK. With regard to the kinetic data, MN58b and RSM- 932A were docked into the active site and choline site alone, respectively using apo-sChoK structure as a model (RCSB accession #4R77). Te entire active site was defned as all of the residues of sChoK known from the crystal structure of sChoK to make contact with both ATP (43, 90, 183, 89, 91, 31, 818, and 194) and choline (residue numbers 197, 251, 254, 268, 178, 213, 29, 176), while the choline site was defned as only those residues making contact with choline.